AMS HP eNews Bulletin 29 September 2016



  Australasian Menopause Society  
Health Professionals eNews29 September 2016
  Welcome to AMS HP eNews for doctors and other healthcare professionals who have a special interest in women's health. The content covers information and resources relevant to menopause, midlife and the promotion of healthy ageing.


20th AMS Congress - Registration open 

AMS Annual Congress  Fremantle - Western Australia 18-20 November 2016Attend our Congress at the Esplanade Hotel in Fremantle, right in the heart of the art and cafe culture of the historic port city and close by to beaches, the Swan river and Rottnest Island. 


Register now

Earlybird registration is open until
30 September





AMS Congress Awards 

At the AMS Congress the following awards will be made: 


Congress Awards 

The Jean Hailes Memorial Prize is presented to the best free communication or poster presentation by a current AMS member who is still within 10 years of having completed their tertiary degree. The presenter is to indicate their eligibility for this prize when submitting their abstract. The winner will receive a certificate of honour and AUD$500.


The Barbara Gross Award is presented to the best overall free communication or poster by a current AMS member. All free communications and posters presented at the Congress by a current AMS member will be entered for this award. The winner will receive a certificate of honour and AUD$1,000.


The Vivien Wallace Poster Prize is given to encourage delegates working in any area of medicine to submit a poster for inclusion in the 2016 Congress program. This is an annual award to the value of AUD$250.


Judges for the Congress Awards are appointed by the Chair of the Scientific Program Committee and there are two judges per room, with a prescribed scoring system.

AMS Awards 

The AMS Scientific Award is given to the most meritorious contribution to the field of menopause by an Australian or New Zealand investigator. This is an annual award based on a published/accepted paper in the past 12 months accepted and in press by 30 June 2016. The paper should be on a specific subject related to menopause. The winner will receive a certificate of honour and AUD$500.00. Applications for the Award should reach the AMS Secretariat by 30 September 2016



Revised Global Consensus Statement on Menopausal Hormone Therapy  

Revised global consensus statement MHTThis Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The Asia Pacific Menopause Federation, The International Osteoporosis Foundation and The Federation of Latin American Menopause Societies.


The publication of the Global Consensus on Menopausal Hormone Therapy in 2013 by leading global menopause societies succeeded in presenting guidelines in a troubled therapeutic area that are helpful to both health-care providers and potential users of menopausal hormone therapy (MHT).


The revised statement is aimed at updating and expanding the areas of consensus. Bullet-point format aims to facilitate ease of use. Only areas of consensus are shown and does not replace the more detailed and fully referenced recommendations of the individual societies (referenced at the end of the document).


Section A: Benefit/risk profile of MHT

Section B: General principles governing the use of MHT 


Hopefully, this statement will enable health-care providers to offer those women in midlife, who may benefit from MHT, the opportunity to make an informed decision.




Join AMS for Member's only content

See exclusive commentary on studies such as:   


Does long-term bisphosphonate treatment increase fracture risk?

The question of how long to treat with bisphosphonates to prevent osteoporosis-related fractures remains unanswered because of present lack of data and the poor prospect of future data. The two main concerns regarding long-term use of bisphosphonates are: (1) Decreasing efficacy of fracture prevention over time. The inhibition of the osteoclast is over time balanced out by inhibition of the osteoblast with the potential of poor bone strength; (2) Increased incidence of atypical (femur shaft) fractures over time... 


Is hormone replacement therapy safe in women with a BRCA mutation?

Birrer and colleagues recently reviewed the available literature on the safety of hormone replacement therapy (HRT) in BRCA carriers [1]. Four publications were considered relevant for the purpose of this review. Studies were done to evaluate the impact of HRT on menopausal symptoms (n = 2) or breast cancer risk (n = 2) after bilateral salpingo-oophorectomy (BSO) in BRCA mutation carriers. The concern of an elevated breast cancer risk among mBRCA carriers on HRT does not appear to be a significant issue based on the limited data available, which indicate that HRT appears to be safe in young mBRCA carriers who have undergone BSO. This was demonstrated best in the Prevention and Observation of Surgical Endpoints study that included 462 female mBRCA carriers, all of whom were followed from time to BSO (note, patients were censored at the time of prophylactic mastectomy) [2]. Within this population, 114 women took HRT, 93 of 155 who had a BSO, and 21 of 307 who did not have a BSO. Compared with the entire cohort, there was no impact on breast cancer risk with HRT among those who underwent a BSO (hazard ratio (HR) 0.37; 95% confidence interval (CI) 0.14-0.96)... 


When and how to propose chemical prevention to women at risk for breast cancer?

The management of women at high risk for breast cancer has evolved during the past years. This management includes the identification of these women and potentially offers them a preventive strategy. Chemical prevention by selective estrogen receptors modulators (SERMs) and aromatase inhibitors (AI) has been shown to decrease the risk of primary breast cancer, precancerous lesions, bilateral breast cancer and recurrence. Despite recommendations to use these treatments for prevention in some countries, a very low number of women use them. The main reason is fear of side-effects. The only alternative so far is surgical mastectomy. A debate was organized at the Beth Israel Deaconess Medical Center to discuss the administration of these preventive medications and how to overcome women’s resistances...


2016 ams congress 1

  Australasian Menopause Society
PO Box 511, Inverloch VIC 3996
Tel: +61 3 9428 8738

  Join the Australasian Menopause Society  
Forward this email to a friend